Trial · NCT00038467
Results by group482
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 482
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study | Exemestane | 0.90 | 95% Confidence Interval 0.89 to 0.92 | probability of DFS | |
| Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study | Tamoxifen | 0.86 | 95% Confidence Interval 0.85 to 0.88 | probability of DFS | |
| Overall Survival (OS) at Month 36 Post-Randomization: Main Study | Exemestane | 0.953 | 95% Confidence Interval 0.945 to 0.962 | probability of OS | |
| Overall Survival (OS) at Month 36 Post-Randomization: Main Study | Tamoxifen | 0.941 | 95% Confidence Interval 0.932 to 0.951 | probability of OS | |
| Number of Events of Second Breast Cancer in Contralateral Breast: Main Study | Exemestane | 57 | events | ||
| Number of Events of Second Breast Cancer in Contralateral Breast: Main Study | Tamoxifen | 75 | events | ||
| Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study | Exemestane | Change at 6 months on-treatment: LS (n=84,96) | -2.64 | Standard Deviation 2.89 | percent change |
| Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study | Tamoxifen | Change at 6 months on-treatment: LS (n=84,96) | -0.22 | Standard Deviation 2.55 | percent change |
| Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study | Exemestane | Change at 6 months on-treatment: TH (n=82,96) | -1.31 | Standard Deviation 2.20 | percent change |
| Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study | Tamoxifen | Change at 6 months on-treatment: TH (n=82,96) | -0.13 | Standard Deviation 1.90 | percent change |
| Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study | Exemestane | Change at 12 months on-treatment: LS (n=82,96) | -2.98 | Standard Deviation 3.30 | percent change |
| Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study | Tamoxifen | Change at 12 months on-treatment: LS (n=82,96) | -0.19 | Standard Deviation 3.53 | percent change |
| Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study | Exemestane | Change at 12 months on-treatment: TH (n=82,95) | -2.17 | Standard Deviation 2.34 | percent change |
| Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study | Tamoxifen | Change at 12 months on-treatment: TH (n=82,95) | -0.39 | Standard Deviation 2.17 | percent change |
| Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study | Exemestane | Change at 24 months on-treatment: LS (n=82,92) | -3.69 | Standard Deviation 4.12 | percent change |
| Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study | Tamoxifen | Change at 24 months on-treatment: LS (n=82,92) | -0.47 | Standard Deviation 3.38 | percent change |
| Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study | Exemestane | Change at 24 months on-treatment: TH (n=79,93) | -2.81 | Standard Deviation 2.61 | percent change |
| Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study | Tamoxifen | Change at 24 months on-treatment: TH (n=79,93) | -0.91 | Standard Deviation 2.66 | percent change |
| Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study | Exemestane | Change at 24 months post-treatment: LS (n=74,81) | -2.17 | Standard Deviation 5.09 | percent change |
| Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study | Tamoxifen | Change at 24 months post-treatment: LS (n=74,81) | -3.44 | Standard Deviation 4.28 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00038467/results